Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [111In]-labeled CHX-A"DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 523-528

  Malmberg, Jennie ^a   Tolmachev, Vladimir ^a   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecule; Cellular processing; DU145; Human epidermal growth factor receptor type 2; In vitro; Indium 111; LNCaP; PC3; Prostate cancer; Trastuzumab

Indexed keywords

ABY 025; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; MONOCLONAL ANTIBODY; PENTETIC ACID; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; HUMAN; HUMAN CELL; MOLECULAR IMAGING; PROSTATE CANCER;

EID: 79953275504     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.217     Document Type: Article

References (34)

1. Taichman RS, Loberg RD, Mehra R and Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest 117: 2351-2361, 2007.
2. Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671, 2006.
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
4. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
5. Pienta KJ and Smith DC: Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-318, 2005.
6. Signoretti S, Montironi R, Manola J, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl cancer Inst 92: 1918-1925, 2000.
7. Scher HI and Sawyers CL: Biology of castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261, 2005.
8. So A, Gleave M, Hurtado-Col A and Nelson C: Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23: 1-9, 2005.
9. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
10. Craft N, Shostak Y, Carey M and Sawyers CL: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285, 1999.
11. Gioeli D, Ficarro SB, Kwiek JJ, et al: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277: 29304-29314, 2002.
12. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
13. Tolmachev V: Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 14: 2999-3011, 2008.
14. Behr TM, Behe M and Wormann B: Trastuzumab and breast cancer. N Engl J Med 345: 995-996, 2001.
15. Tolmachev V and Orlova A: Update on affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotechnologica 21: 21-30, 2009.
16. Nygren PA: Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275: 2668-2676, 2008.
17. Orlova A, Magnusson M, Eriksson TL, et al: Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66: 4339-4348, 2006.
18. 68Ga-labeled Affibody molecules. J Nucl Med 51: 892-897, 2010.
19. Feldwisch J, Tolmachev V, Lendel C, et al: Design of an optimized scaffold for Affibody molecules. J Mol Biol 398: 232-247, 2010.
20. 111In-ABY-025, a second generation Affibody molecule with a fundamentally re-engineered scaffold. J Nucl Med 51: 1131-1138, 2010.
21. Almqvist Y, Steffen AC, Tolmachev V, Divgi CR and Sundin A: In vitro and in vivo characterization of 177Lu-huA33: a radio-immunoconjugate against colorectal cancer. Nucl Med Biol 33: 991-998, 2006.
22. 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23: 435-442, 2008.
23. Agus DB, Scher HI, Higgins B, et al: Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and-independent human xenograft models. Cancer Res 59: 4761-4764, 1999.
24. Liu Y, Majumder S, McCall W, et al: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65: 3404-3409, 2005.
25. Ziada A, Barqawi A, Glode LM, et al: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337, 2004.
26. Lara PN Jr, Chee KG, Longmate J, et al: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and phase II Trial. Cancer 100: 2125-2131, 2004.
27. Sridhar SS, Hotte SJ, Chin JL, et al: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol 33: 609-613, 2010.
28. Visakorpi T, Kallioniemi OP, Koivula T, Harvey J and Isola J: Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 5: 643-648, 1992.
29. Gu K, Mes-Masson AM, Gauthier J and Saad F: Overexpression of HER-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 99: 185-189, 1996.
30. Ahlgren S, Wållberg H, Tran TA, et al: Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 50: 781-789, 2009.
31. Tran TA, Rosik D, Abrahmsén L, et al: Design, synthesis and biological evaluation of a multifunctional HER2-specific Affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36: 1864-1873, 2009.
32. Austin CD, de Maziere AM, Pisacane PI, et al: Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15: 5268-5282, 2004.
33. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al: Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 143: 99-106, 2004.
34. Orlova A, Wållberg H, Stone-Elander S and Tolmachev V: On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 50: 417-425, 2009.